Charles Schwab Investment Management Inc. Grows Stock Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Charles Schwab Investment Management Inc. increased its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 2.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 948,451 shares of the company’s stock after buying an additional 23,675 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Organogenesis were worth $2,713,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Acadian Asset Management LLC raised its position in shares of Organogenesis by 2.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after buying an additional 72,696 shares during the period. AQR Capital Management LLC raised its position in Organogenesis by 76.9% in the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after purchasing an additional 986,132 shares during the period. Dimensional Fund Advisors LP raised its position in Organogenesis by 19.6% in the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after purchasing an additional 333,123 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in Organogenesis by 5.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 471,240 shares of the company’s stock valued at $1,348,000 after purchasing an additional 24,878 shares during the period. Finally, Wealth Dimensions Group Ltd. raised its position in Organogenesis by 435.9% in the second quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company’s stock valued at $1,142,000 after purchasing an additional 331,840 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Insider Buying and Selling at Organogenesis

In other Organogenesis news, CEO Gary S. Gillheeney sold 41,052 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $3.52, for a total value of $144,503.04. Following the completion of the transaction, the chief executive officer now owns 3,359,726 shares in the company, valued at $11,826,235.52. This represents a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 216,916 shares of company stock worth $784,832 over the last 90 days. Corporate insiders own 36.90% of the company’s stock.

Organogenesis Stock Down 3.7 %

Shares of NASDAQ ORGO opened at $3.40 on Monday. The firm has a market cap of $450.77 million, a price-to-earnings ratio of -56.67 and a beta of 1.73. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a 52-week low of $2.16 and a 52-week high of $4.70. The business’s 50 day moving average is $3.43 and its two-hundred day moving average is $2.99.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The company had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. During the same quarter in the previous year, the company earned $0.02 earnings per share. Research analysts predict that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.